Press Releases

16 Nov 2022

Antimicrobial Resistance

Survey bioMérieux OpinionWay - Antimicrobial Resistance and diagnostic tests

To mark World Antimicrobial Awareness Week organized by the WHO from November 18-24, bioMérieux presents the results of a bioMérieux/OpinionWay survey on the general public's knowledge of antimicrobial resistance and the use of diagnostic tests in France.

26 Oct 2022

Financial Information

Third-quarter 2022 Business Review

bioMérieux, a world leader in the field of in vitro diagnostics, releases its business review for the nine months ended September 30, 2022.

26 Sep 2022

Sepsis

New survey shows low adherence to guidelines in sepsis care puts patients at risk

To mark Sepsis Awareness Month, bioMérieux, a world leader in in vitro diagnostics with a long-standing commitment to the fight against sepsis, and the UK Sepsis Trust, an internationally renowned charity, have released new survey data of health professionals to assess their knowledge and practice in the management of sepsis. This survey was commissioned among 368 doctors across six European countries.

31 Aug 2022

Financial Information

First-Half 2022 Results

The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on August 30 under the chairmanship of Alexandre Mérieux and approved the consolidated financial statements for the six months ended June 30, 2022.

22 Aug 2022

Antimicrobial Resistance

The SPECIFIC REVEAL® Rapid AST System has received Breakthrough Device Designation from the U.S. Food and Drug Administration

bioMérieux, a world leader in the field of in vitro diagnostics, today announces that the U.S. Food and Drug Administration (FDA) has granted its Breakthrough Device Designation for the SPECIFIC REVEAL® Rapid Antimicrobial Susceptibility Test (AST) System.

28 Jul 2022

Business & Solutions